CoChat

Epilepsy Gene Therapy Using an Engineered Potassium Channel

Open access
Snowball, Albert, Chabrol, Elodie, Wykes, Robert C., Shekh-Ahmad, Tawfeeq, Cornford, Jonathan H., Lieb, Andreas, Hughes, Michael P., Massaro, Giulia, Rahim, Ahad A., Hashemi, Kevan S., Kullmann, Dimitri M., Walker, Matthew C., Schorge, Stephanie · 2019 · The Journal of Neuroscience
Cited by 127

The DOI matches its Crossref record; 14 of the 14 references it cites were found in a registry or an index.

Abstract

Refractory focal epilepsy is a devastating disease for which there is frequently no effective treatment. Gene therapy represents a promising alternative, but treating epilepsy in this way involves irreversible changes to brain tissue, so vector design must be carefully optimized to guarantee safety without compromising efficacy. We set out to develop an epilepsy gene therapy vector optimized for clinical translation. The gene encoding the voltage-gated potassium channel Kv1.1, KCNA1 , was codon optimized for human expression and mutated to accelerate the recovery of the channels from inactivation. For improved safety, this engineered potassium channel (EKC) gene was packaged into a nonintegrating lentiviral vector under the control of a cell type-specific CAMK2A promoter. In a blinded, randomized, placebo-controlled preclinical trial, the EKC lentivector robustly reduced seizure frequency in a male rat model of focal neocortical epilepsy characterized by discrete spontaneous seizures. When packaged into an adeno-associated viral vector (AAV2/9), the EKC gene was also effective at suppressing seizures in a male rat model of temporal lobe epilepsy. This demonstration of efficacy in a clinically relevant setting, combined with the improved safety conferred by cell type-specific expression and integration-deficient delivery, identify EKC gene therapy as being ready for clinical translation in the treatment of refractory focal epilepsy. SIGNIFICANCE STATEMENT Pharmacoresistant epilepsy affects up to 0.3% of the population. Although epilepsy surgery can be effective, it is limited by risks to normal brain function. We have developed a gene therapy that builds on a mechanistic understanding of altered neuronal and circuit excitability in cortical epilepsy. The potassium channel gene KCNA1 was mutated to bypass post-transcriptional editing and was packaged in a nonintegrating lentivector to reduce the risk of insertional mutagenesis. A randomized, blinded preclinical study demonstrated therapeutic effectiveness in a rodent model of focal neocortical epilepsy. Adeno-associated viral delivery of the channel to both hippocampi was also effective in a model of temporal lobe epilepsy. These results support clinical translation to address a major unmet need.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1523/jneurosci.1143-18.2019

Cites

14 of 14 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 14 references

Cited by

See all 127

Metadata

Authors
Snowball, A., Chabrol, E., Wykes, R. C., Shekh-Ahmad, T., Cornford, J. H., Lieb, A., Hughes, M. P., Massaro, G., Rahim, A. A., Hashemi, K. S., Kullmann, D. M., Walker, M. C., & Schorge, S.
Venue
The Journal of Neuroscience
Published
2019-02-12
Volume
39
Issue
16
Pages
3159-3169
ISSN
  • 0270-6474 (ISSN-L)
  • 1529-2401
OpenAlex
W2911671193
Cited by
127
References
14
FWCI
6.77
Type
journal article
Language
en
Open access
hybrid

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Epilepsy Gene Therapy Using an Engineered Potassium Channel. https://app.cochat.ai/papers/10.1523/jneurosci.1143-18.2019
The paper
Snowball, A., Chabrol, E., Wykes, R. C., Shekh-Ahmad, T., Cornford, J. H., Lieb, A., Hughes, M. P., Massaro, G., Rahim, A. A., Hashemi, K. S., Kullmann, D. M., Walker, M. C., & Schorge, S. (2019). Epilepsy Gene Therapy Using an Engineered Potassium Channel. The Journal of Neuroscience. https://doi.org/10.1523/jneurosci.1143-18.2019

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.